机构：[1]State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China.[2]Northeast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China.[3]The First Clinical Medical College, The First Hospital Affiliated, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.深圳市中医院深圳医学信息中心[4]School of Pharmacy, Department of Medical Oncology, Hangzhou Normal University, Hangzhou 311121, China.[5]Cancer Center, Faculty of Health Science, MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau 999078, China.[6]Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Guangdong University of Technology, Guangzhou 510006, China.[7]Zhuhai MUST Science and Technology Research Institute, Zhuhai 519031, China.
Tumor metastasis occurs in lung cancer, resulting in tumor progression and therapy failure. Anoikis is a mechanism of apoptosis that combats tumor metastasis; it inhibits the escape of tumor cells from the native extracellular matrix to other organs. Deciphering the regulators and mechanisms of anoikis in cancer metastasis is urgently needed to treat lung cancer. Several natural and synthetic products exhibit the pro-anoikis potential in lung cancer cells and in vivo models. These products include artonin E, imperatorin, oroxylin A, lupalbigenin, sulforaphane, renieramycin M, avicequinone B, and carbenoxolone. This review summarizes the current understanding of the molecular mechanisms of anoikis regulation and relevant regulators involved in lung cancer metastasis and discusses the therapeutic potential of targeting anoikis in the treatment of lung cancer metastasis.
基金：
This research was funded by the Natural Science Foundation of Jilin Province (grant number
YDZJ202101ZYTS035); the Education Department of Jilin Province (grant number JJKH20210983KJ); the
Science and Technology Development Fund, Macau SAR (grant number 0168/2019/A3, 0099/2018/A3,
0098/2021/A2, and 130/2017/A3); and the Science and Technology Planning Project of Guangdong
Province (grant number 2020B1212030008).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|2 区医学
小类|3 区肿瘤学
最新[2025]版：
大类|3 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China.[2]Northeast Asia Research Institute of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun 130117, China.
共同第一作者：
通讯作者：
通讯机构：[1]State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China.[6]Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Guangdong University of Technology, Guangzhou 510006, China.[7]Zhuhai MUST Science and Technology Research Institute, Zhuhai 519031, China.
推荐引用方式(GB/T 7714)：
Wang Jing,Luo Zhijie,Lin Lizhu,et al.Anoikis-Associated Lung Cancer Metastasis: Mechanisms and Therapies[J].Cancers.2022,14(19):doi:10.3390/cancers14194791.
APA：
Wang Jing,Luo Zhijie,Lin Lizhu,Sui Xinbing,Yu Lili...&Wu Qibiao.(2022).Anoikis-Associated Lung Cancer Metastasis: Mechanisms and Therapies.Cancers,14,(19)
MLA：
Wang Jing,et al."Anoikis-Associated Lung Cancer Metastasis: Mechanisms and Therapies".Cancers 14..19(2022)
